Medicine and Dentistry
Systematic Review
100%
Meta-Analysis
83%
Prostate Cancer
62%
Overall Survival
51%
Immune Checkpoint Inhibitor
51%
Kidney Metastasis
49%
Network Meta-Analysis
35%
Systemic Therapy
29%
Randomized Controlled Trial
29%
Combination Therapy
28%
Clear Cell Renal Cell Carcinoma
26%
Transitional Cell Carcinoma
26%
Radical Nephrectomy
26%
Neoplasm
26%
Prostatectomy
25%
Progression Free Survival
24%
Metastatic Carcinoma
23%
Recurrent Disease
22%
Nivolumab
22%
Immunotherapy
19%
Kidney Cancer
19%
Cabozantinib
19%
Retroperitoneal Lymph Node Dissection
17%
Non Muscle Invasive Bladder Cancer
17%
Radiation Therapy
17%
Ipilimumab
17%
Hazard Ratio
16%
Disease
15%
Androgen Deprivation Therapy
14%
Surgery
14%
Adverse Event
14%
Bladder
14%
Androgen Receptor
13%
Cancer Diagnosis
13%
Nephroureterectomy
12%
Pembrolizumab
12%
Diagnosis
12%
Infection
11%
Local Therapy
11%
Adjuvant Therapy
11%
Propensity Score Matching
11%
Prostate Specific Antigen
10%
Transurethral Resection
10%
Bleeding
10%
Antibiotics
10%
Survival Rate
9%
Urinary Tract Infection
9%
Biological Marker
9%
Symptom
9%
Cancer Specific Survival
9%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
66%
Immune Checkpoint Inhibitor
58%
Kidney Metastasis
53%
Prostate Cancer
35%
Non Muscle Invasive Bladder Cancer
35%
Combination Therapy
34%
Randomized Controlled Trial
32%
Adverse Event
29%
Renal Cell Carcinoma
28%
Progression Free Survival
27%
Transitional Cell Carcinoma
25%
Nivolumab
22%
Pembrolizumab
20%
Cabozantinib
19%
Cancer Specific Survival
18%
Immunotherapy
17%
Mycobacterium Bovis BCG
17%
Ipilimumab
17%
Proton Pump Inhibitor
15%
Neoplasm
15%
Malignant Neoplasm
15%
Chemotherapy
15%
Disease
14%
Androgen
13%
Androgen Receptor
12%
Recurrence Risk
12%
Infection
11%
Epirubicin
11%
Protein Tyrosine Kinase Inhibitor
10%
Monotherapy
10%
Antibiotics
9%
Recurrent Disease
9%
Kidney Cancer
8%
Recurrence Free Survival
8%
Bleeding
8%
Endocrine Therapy
8%
Pharmacovigilance
8%
Germ Cell Tumor
8%
Seminoma
8%
Gleason Score
8%
Plasma Cell Granuloma
8%
Antacid Agent
8%
Urinary Tract Infection
8%
Renin-Angiotensin System Inhibitor
8%
Postoperative Infection
8%
Surgical Infection
8%
Lenvatinib
8%
Survival Rate
7%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
7%
Beta Adrenergic Receptor Blocking Agent
7%
Keyphrases
Metastatic Renal Cell Carcinoma (mRCC)
35%
Systematic Meta-analysis
31%
Meta-analysis
30%
Immune Checkpoint Inhibitors
30%
Network Meta-analysis
26%
Overall Survival
21%
Non-muscle Invasive Bladder Cancer (NMIBC)
17%
Triplet Therapy
17%
First-line Immunotherapy
17%
Renal Cell Carcinoma
17%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
17%
Intermediate Risk
15%
Intravesical Therapy
11%
Randomized Controlled Trial
11%
Progression-free Survival
11%
Propensity Score Matching
11%
Meta-network
10%
Recurrence-free Survival
10%
Safety Outcomes
10%
Urinary Tract Infection
9%
Combination Therapy
9%
Brachytherapy Seeds
8%
Geriatric nutritional Risk Index
8%
Disease Impact
8%
Lupus Cystitis
8%
Urachus
8%
Radical Nephrectomy
8%
Immune Checkpoint Inhibitor Combination Therapy
8%
Adjuvant Therapy
8%
Advanced Renal Cancer
8%
Prognostic Marker
8%
Muscular Development
8%
Urinary Calculosis
8%
Trans Men
8%
Primary Retroperitoneal
8%
Valdivia
8%
Cabozantinib
8%
Body Composition Changes
8%
Cytoreductive Radical Prostatectomy
8%
Permanent Prostate Brachytherapy
8%
Real-world Pharmacovigilance
8%
Retrospective multicenter Study
8%
Laparoscopic Radical Cystectomy
8%
Urinary Bladder Cancer
8%
Efficacy Outcomes
8%
Bladder Tuberculosis
8%
Pagetoid Spread
8%
Intravesical Chemotherapy
8%
Testicular Hemorrhage
8%
Bladder Cancer Therapy
8%